A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, cancer, colonic disorder, colonic neoplasm, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, intestinal disorder, lung disorder, lung neoplasm, malignant colon neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, non-small cell lung carcinoma, pancreas disorder, pancreatic neoplasm, rectal disorder, respiratory system disorder, respiratory tract neoplasm	Active, not recruiting	Phase 1	2025-09-24		NCT05163028

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
HUYABIO International, LLC.	4

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
BRCR Medical Center	Plantation	United States	6
California Cancer Associates for Research and Excellence, Inc. (cCare)	San Marcos	United States	3
California Cancer Associates for Research and Excellence, Inc. (cCARE)	Encinitas	United States	3
City of Hope	Duarte	United States	238
Gabrail Cancer Center	Canton	United States	39
Orlando Health, Inc.	Orlando	United States	8
Pan American Center for Oncology Trials (PanOncology Trials)	Rio Piedras	Puerto Rico	2
Providence Medical Foundation	Fullerton	United States	46
Sarcoma Oncology	Santa Monica	United States	2
Texas Oncology - Tyler	Tyler	United States	14
UCLA Hematology/Oncology	Santa Monica	United States	3
Virginia Cancer Specialists	Fairfax	United States	109